Zimmer Biomet’s (ZBH) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research restated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a report issued on Thursday morning,Benzinga reports. They currently have a $112.00 price objective on the medical equipment provider’s stock.

Several other research analysts have also weighed in on the company. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a research report on Wednesday, November 5th. Baird R W cut Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 16th. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Sunday, November 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $108.30.

Zimmer Biomet Trading Up 1.5%

Shares of ZBH opened at $94.07 on Thursday. Zimmer Biomet has a 12-month low of $85.33 and a 12-month high of $114.44. The firm has a market capitalization of $18.64 billion, a P/E ratio of 23.28, a P/E/G ratio of 2.36 and a beta of 0.62. The firm has a 50-day moving average price of $92.20 and a 200 day moving average price of $96.55. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.02. The company had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. Zimmer Biomet’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts forecast that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be issued a $0.24 dividend. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legacy Wealth Asset Management LLC increased its stake in shares of Zimmer Biomet by 2.3% during the third quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock worth $460,000 after buying an additional 106 shares during the period. Global Retirement Partners LLC grew its holdings in Zimmer Biomet by 7.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 111 shares in the last quarter. Cullen Frost Bankers Inc. grew its holdings in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares in the last quarter. Generali Asset Management SPA SGR increased its position in shares of Zimmer Biomet by 0.9% in the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock valued at $1,402,000 after purchasing an additional 122 shares during the last quarter. Finally, Brookstone Capital Management raised its holdings in shares of Zimmer Biomet by 1.3% in the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock valued at $921,000 after purchasing an additional 123 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.